Last reviewed · How we verify

NCT04890275

Blood Flow Restricted Resistance Training in Peripheral Arterial Disease

Completed NA Last updated 8 November 2022
What this trial tests

NA trial testing Blood flow restricted resistance exercise (BFR) in Peripheral Arterial Disease in 30 participants. Completed in 30 April 2022.

Timeline
21 April 2021
Primary endpoint
5 March 2022
30 April 2022

Quick facts

Lead sponsorSheffield Hallam University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date21 April 2021
Primary completion5 March 2022
Estimated completion30 April 2022
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Sheffield Hallam University

Who can join

18 and older, any sex, with Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomised controlled trial evaluating the feasibility and acceptability of a 12 week lower body blood flow restricted resistance exercise programme for people with peripheral arterial disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Low-intensity resistance exercise with blood flow restriction for patients with claudication: A randomized controlled feasibility trial.
    Parkington T, Broom D, Maden-Wilkinson T, Nawaz S, et al · · 2023 · cited 4× · PMID 37819259 · DOI 10.1177/1358863x231200250

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

Other Sheffield Hallam University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04890275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing